The introduction of "Ado sulfate enzyme beta injection" by Beihai Kangcheng is about to be approved in China.

On August 28th Beihai Kangcheng submitted a new application for the listing of a new drug called HunterAse beta injection for the treatment of Hunter Syndrome, which is expected to be approved in China in the near future.
has been included in China's "first list of rare diseases", but at present, China has not approved the treatment of Hunter syndrome treatment program.
January 7, 2019, Beihai Kangcheng signed an exclusive license agreement for Greater China with GC Pharma of South Korea, the developer of Adolfate beta injections, with exclusive commercial rights.
acetosterase beta injection is a recombinant human Adulycate-2-Sulphate enzyme replacement therapy.
syndrome (Mucosal polysaccharidism type II, MPS II) is a rare, disabling and fatal genetic disorder that is more common in Asian countries.
is available in 10 countries.
(Slim Polysaccharide Storage Type II, MPS II) is a hereditary lysosome storage disorder (LSD) caused by a deficiency of 2-sulphate enzymes.
2-sulfatease is an enzyme needed to break down the body called glycamine polysaccharides (GAGs), without which GAG accumulates and causes serious bone, tissue, nerve and multi-organ complications that eventually lead to death.
the incidence of Hunter syndrome in East Asian countries is high, the incidence rate in Taiwan is about 1/51000-1/93000.
the disease is not currently curable, standard therapy is enzyme replacement therapy or palliative care.
original title: New drug for rare diseases! The introduction of "Ado sulfate enzyme beta injection" by Beihai Kangcheng is about to be approved in China.